Abstract
The cancer stem cell (CSC) hypothesis provides an attractive model of tumor development and progression, holding that solid tumors are hierarchically organized and sustained by a minority of the tumor cell population with stem cell properties, such as self-renewal, tumorigenicity and multilineage differentiation capacity. Therapeutic resistance, underlying tumor recurrence and the lack of curative treatments in metastatic disease, raise the question if conventional anticancer therapies target the right cells. Indeed, these treatments might miss CSCs, which represent a more chemoresistant and radioresistant subpopulation within cancer. Recently, a direct link between the epithelial-mesenchymal transition process and the gain of stem cell competence were demonstrated in cultured breast cells. In particular, it was shown that the induction of EMT program not only allows cancer cells to disseminate from the primary tumor, but also promotes their self-renewal capability. Furthermore, the expression of stemness and EMT markers in CTCs were associated with resistance to conventional anti-cancer therapies and treatment failure, highlighting the urgency of improving tools for detecting and eliminating minimal residual disease.
Keywords: Cancer stem cells, epithelial-mesenchymal transition, tumor microenvironment
Current Cancer Drug Targets
Title: Cancer Stem Cells and Epithelial-Mesenchymal Transition: Revisiting Minimal Residual Disease
Volume: 10 Issue: 5
Author(s): C. Raimondi, W. Gianni, E. Cortesi and P. Gazzaniga
Affiliation:
Keywords: Cancer stem cells, epithelial-mesenchymal transition, tumor microenvironment
Abstract: The cancer stem cell (CSC) hypothesis provides an attractive model of tumor development and progression, holding that solid tumors are hierarchically organized and sustained by a minority of the tumor cell population with stem cell properties, such as self-renewal, tumorigenicity and multilineage differentiation capacity. Therapeutic resistance, underlying tumor recurrence and the lack of curative treatments in metastatic disease, raise the question if conventional anticancer therapies target the right cells. Indeed, these treatments might miss CSCs, which represent a more chemoresistant and radioresistant subpopulation within cancer. Recently, a direct link between the epithelial-mesenchymal transition process and the gain of stem cell competence were demonstrated in cultured breast cells. In particular, it was shown that the induction of EMT program not only allows cancer cells to disseminate from the primary tumor, but also promotes their self-renewal capability. Furthermore, the expression of stemness and EMT markers in CTCs were associated with resistance to conventional anti-cancer therapies and treatment failure, highlighting the urgency of improving tools for detecting and eliminating minimal residual disease.
Export Options
About this article
Cite this article as:
Raimondi C., Gianni W., Cortesi E. and Gazzaniga P., Cancer Stem Cells and Epithelial-Mesenchymal Transition: Revisiting Minimal Residual Disease, Current Cancer Drug Targets 2010; 10 (5) . https://dx.doi.org/10.2174/156800910791517154
DOI https://dx.doi.org/10.2174/156800910791517154 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical and Serological Biomarkers of Treatment’s Response in Multiple Sclerosis Patients Treated Continuously with Interferonβ-1b for More than a Decade
CNS & Neurological Disorders - Drug Targets Cardiac Toxicities of Antiangiogenic Therapies
Current Angiogenesis (Discontinued) Effect of Prostaglandins on the Regulation of Tumor Growth
Current Medicinal Chemistry - Anti-Cancer Agents Plasma Proteins Interaction with Curcumin Nanoparticles: Implications in Cancer Therapeutics
Current Drug Metabolism Somatic Mutations, Viral Integration and Epigenetic Modification in the Evolution of Hepatitis B Virus-Induced Hepatocellular Carcinoma
Current Genomics The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies
Current Cancer Drug Targets Subject Index To Volume 1
Recent Patents on Anti-Cancer Drug Discovery Prevention of Intracerebral Haemorrhage
Current Drug Targets Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors
Current Pharmaceutical Design Copper-Catalyzed Azide-Alkyne Cycloaddition (CuAAC)-Mediated Macrocyclization of Peptides: Impact on Conformation and Biological Activity
Current Topics in Medicinal Chemistry Cow’s Milk Allergy in Children, from Avoidance to Tolerance
Endocrine, Metabolic & Immune Disorders - Drug Targets Psychological Sequelae of Ovarian Cancer Screening and Genetic Testing for Ovarian Cancer Susceptibility
Current Women`s Health Reviews Acknowledgements to Reviewers
Anti-Cancer Agents in Medicinal Chemistry The Emerging Role of Bcr-Abl-Induced Cystoskeletal Remodeling in Systemic Persistence of Leukemic Stem Cells
Current Drug Delivery Mesalamine for Inflammatory Bowel Disease: Recent Reappraisals
Inflammation & Allergy - Drug Targets (Discontinued) Lysophosphatidic Acid and Renal Fibrosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Recent Advances in the Development of Selective Small Molecule Inhibitors for Cyclin-Dependent Kinases
Current Topics in Medicinal Chemistry Targeted Delivery of siRNA Therapeutics using Ligand Mediated Biodegradable Polymeric Nanocarriers
Current Pharmaceutical Design Using Feature Selection Technique for Drug-Target Interaction Networks Prediction
Current Medicinal Chemistry Editorial
Current Radiopharmaceuticals